On Jan 27, 2022 Simcha Therapeutics closed a Series B round and raised $40,000,000 from ArrowMark Partners, BVF Partners, Logos Capital, Rock Springs Capital, Samsara BioCapital, SR One, featuring lead investors SR One.

About the company: Simcha Therapeutics is located at United States, North America.
“Unlocking the full potential of the immune system with directed evolution.”

Company website: http://www.simchatx.com